Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082992 | 0.85 | PPARD (0.50) | PPARDESR1NPSR1ALDH1A1HPGD | |
| SCHEMBL2354034 | 0.81 | PPARD (0.83) | PPARDESR1PPARA | |
| SCHEMBL5974797 | 0.74 | ESR1 (0.55) | PPARDESR1NPSR1GAAALDH1A1 | |
| SCHEMBL13087141 | 0.73 | PPARD (0.82) | PPARDPPARA | |
| SCHEMBL12059023 | 0.73 | ESR1 (0.54) | PPARDESR1NPSR1GAAALDH1A1 | |
| SCHEMBL5992812 | 0.72 | ESR1 (0.43) | PPARDESR1NPSR1GAAALDH1A1 | |
| SCHEMBL5991573 | 0.72 | ESR1 (0.43) | PPARDESR1NPSR1GAAALDH1A1 | |
| SCHEMBL14527871 | 0.72 | ESR1 (0.53) | PPARDESR1NPSR1ALDH1A1KDM4E | |
| SCHEMBL3681632 | 0.71 | ESR1 (0.50) | PPARDESR1NPSR1ALDH1A1KDM4E | |
| SCHEMBL3583564 | 0.71 | ESR1 (0.50) | PPARDESR1NPSR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243766-B1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids for use in treating PPAR-delta mediated conditions | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-8450371-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450371-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20120322875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2012-12-20 | — | — | US | disclosed |
| US-8258177-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| US-8008513-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-30 | — | — | US | disclosed |
| US-8008513-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-30 | — | — | US | disclosed |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-7598292-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-06 | — | — | US | disclosed |
| US-7598292-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-06 | — | — | US | disclosed |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885ESR1 1565/4885NPSR1 2330/4885 |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885ESR1 1565/4885NPSR1 2330/4885 |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885ESR1 1565/4885NPSR1 2330/4885 |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARD 3/4885ESR1 1565/4885NPSR1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.